
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell RNA sequencing dataset of breast cancer tissue, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **VWF (von Willebrand factor):** A glycoprotein involved in hemostasis, typically expressed in endothelial cells.<br>- **CD34:** A cell surface glycoprotein often used as a marker for hematopoietic progenitor cells and endothelial cells.<br>- **PECAM1 (CD31):** An adhesion molecule expressed on endothelial cells and involved in leukocyte transmigration.<br>- **KDR (VEGFR2):** A receptor for vascular endothelial growth factor, crucial for angiogenesis, typically expressed in endothelial cells.<br>- **FLT1 (VEGFR1):** Another receptor for VEGF, involved in angiogenesis and endothelial cell function.<br>- **NOTCH4:** Part of the Notch signaling pathway, important in vascular development and endothelial cell function.<br>- **ESAM (Endothelial cell-selective adhesion molecule):** Involved in endothelial cell junctions and angiogenesis.<br>- **PLVAP (Plasmalemma vesicle-associated protein):** Associated with fenestral diaphragms of endothelial cells.<br>- **TIE1 and TIE2 (TEK):** Receptors involved in angiogenesis and endothelial cell survival.<br>- **ENG (Endoglin):** A component of the TGF-beta receptor complex, expressed in endothelial cells.<br>- **SPARC (Secreted protein acidic and rich in cysteine):** Involved in tissue remodeling and angiogenesis.<br><br>### Step 2: List the Key Cell Type Markers<br>- **VWF, CD34, PECAM1, KDR, FLT1, NOTCH4, ESAM, PLVAP, TIE1, ENG:** These markers are strongly indicative of endothelial cells, which line blood vessels and are involved in angiogenesis.<br>- **CLEC14A, EMCN (Endomucin), CDH5 (VE-cadherin), CLDN5 (Claudin-5):** Additional markers supporting endothelial identity, involved in cell adhesion and vascular integrity.<br><br>### Step 3: Cross-reference Known Databases<br>- **Human Protein Atlas and PanglaoDB:** These databases confirm that the expression of VWF, CD34, PECAM1, KDR, FLT1, and other markers are characteristic of endothelial cells.<br>- **Literature Review:** Studies on breast cancer microenvironment often highlight the role of endothelial cells in tumor angiogenesis, supporting the presence of these markers in endothelial cells within breast cancer tissue.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>- **Endothelial Cells:** The expression of VWF, CD34, PECAM1, KDR, FLT1, and other endothelial-specific markers strongly suggests that the general cell type is endothelial cells.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Vascular Endothelial Cells:** Given the high expression of angiogenesis-related markers (e.g., KDR, FLT1, TIE1), these are likely the most prevalent subtype.<br>2. **Lymphatic Endothelial Cells:** Markers like PROX1 and LYVE1, which are not listed here, would be more specific, but the presence of general endothelial markers could still suggest a subset of lymphatic endothelial cells.<br>3. **Tip Cells:** These are specialized endothelial cells involved in sprouting angiogenesis, characterized by high expression of VEGF receptors and other angiogenic markers.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The ranked marker list from the breast cancer tissue dataset predominantly features markers associated with endothelial cells, particularly those involved in angiogenesis. The presence of VWF, CD34, PECAM1, KDR, FLT1, and other related markers strongly indicates that the cell cluster is composed of endothelial cells. Within this general cell type, the most probable subtypes are vascular endothelial cells, potentially involved in tumor angiogenesis, followed by lymphatic endothelial cells and tip cells.<br><br>**Most Likely Subtype:** Vascular Endothelial Cells<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. The markers listed in the annotation, such as VWF, CD34, PECAM1, KDR, FLT1, NOTCH4, ESAM, PLVAP, TIE1, ENG, and SPARC, are all present in the provided marker list and are well-known markers for endothelial cells. The additional markers mentioned, such as CLEC14A, EMCN, CDH5, and CLDN5, further support the endothelial identity.<br><br>The annotation correctly identifies the general cell type as endothelial cells, which is supported by the high-ranking markers associated with angiogenesis and endothelial cell function. The consideration of subtypes such as vascular endothelial cells, lymphatic endothelial cells, and tip cells is reasonable given the context and the expression of angiogenesis-related markers.<br><br>There is no indication of mixed cell types that would require further investigation, as the markers strongly support a single cell type identity. Therefore, the annotation is validated as accurate and consistent with the provided data.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Endothelial Cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Vascular Endothelial Cells</li><li>Lymphatic Endothelial Cells</li><li>Tip Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">95</div>
                        <div class="scoring-content">
                            The annotation results provided for the single-cell RNA sequencing dataset from breast cancer tissue are largely accurate and well-reasoned. The analysis correctly identifies the main cell type as endothelial cells, which is supported by the presence of key markers such as VWF, CD34, PECAM1, KDR, and FLT1. These markers are well-known for their association with endothelial cells and angiogenesis, which is a critical process in tumor biology, particularly in the context of breast cancer.<br><br>The annotation process demonstrates a balanced consideration of multiple markers, rather than over-focusing on a single one. The inclusion of additional markers like CLEC14A, EMCN, CDH5, and CLDN5 further supports the endothelial identity and shows a comprehensive approach to marker analysis. The use of databases such as the Human Protein Atlas and PanglaoDB to cross-reference marker expression adds robustness to the annotation.<br><br>The identification of subtypes, including vascular endothelial cells, lymphatic endothelial cells, and tip cells, is reasonable given the context and the expression of angiogenesis-related markers. However, the absence of specific markers for lymphatic endothelial cells, such as PROX1 and LYVE1, is noted, although the analysis acknowledges this limitation.<br><br>The annotation captures the general picture of the cell populations present, focusing on the role of endothelial cells in the tumor microenvironment. There are no obvious misclassifications or oversights, and the analysis considers the rank of the markers, with high-ranking markers being given appropriate weight in the final annotation.<br><br>Overall, the annotation is scientifically accurate, well-balanced, and provides a comprehensive view of the cell types present in the dataset. The analysis is thorough and considers the importance of marker ranking, which is crucial for accurate cell type identification.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    